Matthew Splett

A study supported by Dr. Jay McLaughlin aims to accelerate the drug development timeline for enhanced version of naloxone.

Using mouse models, Dr. Marco Bortolato and his lab showed in Molecular Psychiatry that CELSR3, a high-confidence risk gene for Tourette syndrome, leads to tic-like behaviors by altering the distribution of dopamine D3 receptors. These data point to D3 receptors as a promising therapeutic target in Tourette syndrome.

ACS Chemical Neuroscience chose artwork from Dr. Leslie Sombers’ latest publication to appear on the journal’s cover.

The agreement aims to foster international collaboration in space research, in-space manufacturing and space-related workforce development.

This prestigious honor recognizes Burris for his innovative research in nuclear receptor biology and its impact on therapeutic development.

Thomas Burris, Ph.D., will lead the new UF Genetics Training Program supported by a T32 grant from the National Institute of General Medical Sciences.

In a study published June 30 in the PNAS journal, Dr. Jay McLaughlin and a team of scientists demonstrate how a single-atom swap in morphine’s structure leads to carbamorphine, a new compound with pain relief benefits but fewer side effects.

The new name better reflects the department’s research scope and strengthens its efforts to recruit graduate students and postdoctoral fellows.

A new study in Nature Communications outlines how UF scientists, including Dr. Jay McLaughlin, are developing safer and better pain medications.

The study led by Dr. Marco Bortolato was published in the journal Molecular Psychiatry on March 28.